View Item 

Show simple item record

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
dc.contributor.authorVij, Ravien_US
dc.contributor.authorSiegel, David S.en_US
dc.contributor.authorJagannath, Sundaren_US
dc.contributor.authorJakubowiak, Andrzej J.en_US
dc.contributor.authorStewart, Alexander Keithen_US
dc.contributor.authorMcDonagh, Kevinen_US
dc.contributor.authorBahlis, Nizaren_US
dc.contributor.authorBelch, Andrewen_US
dc.contributor.authorKunkel, Lori A.en_US
dc.contributor.authorWear, Sandraen_US
dc.contributor.authorWong, Alvin F.en_US
dc.contributor.authorWang, Michaelen_US
dc.date.accessioned2012-09-05T14:46:17Z
dc.date.available2013-10-18T17:47:30Zen_US
dc.date.issued2012-09en_US
dc.identifier.citationVij, Ravi; Siegel, David S.; Jagannath, Sundar; Jakubowiak, Andrzej J.; Stewart, Alexander Keith; McDonagh, Kevin; Bahlis, Nizar; Belch, Andrew; Kunkel, Lori A.; Wear, Sandra; Wong, Alvin F.; Wang, Michael (2012). "An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib." British Journal of Haematology 158(6): 739-748. <http://hdl.handle.net/2027.42/93582>en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/93582
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherAmerican Cancer Society Incen_US
dc.subject.otherMultiple Myelomaen_US
dc.subject.otherProteasome Inhibitoren_US
dc.subject.otherRelapseden_US
dc.subject.otherRefractoryen_US
dc.subject.otherPhase 2en_US
dc.titleAn open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomiben_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22845873en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93582/1/bjh9232.pdf
dc.identifier.doi10.1111/j.1365-2141.2012.09232.xen_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceO'Connor, O.A., Stewart, A.K., Vallone, M., Molineaux, C.J., Kunkel, L.A., Gerecitano, J.F. & Orlowski, R.Z. ( 2009 ) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR‐171) in patients with hematologic malignancies. Clinical Cancer Research, 15, 7085 – 7091.en_US
dc.identifier.citedreferenceDispenzieri, A., Rajkumar, S.V., Gertz, M.A., Fonseca, R., Lacy, M.Q., Bergsagel, P.L., Kyle, R.A., Greipp, P.R., Witzig, T.E., Reeder, C.B., Lust, J.A., Russell, S.J., Hayman, S.R., Roy, V., Kumar, S., Zeldenrust, S.R., Dalton, R.J. & Stewart, A.K. ( 2007 ) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk‐adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings, 82, 323 – 341.en_US
dc.identifier.citedreferencevan de Donk, N.W., Lokhorst, H.M., Dimopoulos, M., Cavo, M., Morgan, G., Einsele, H., Kropff, M., Schey, S., Avet‐Loiseau, H., Ludwig, H., Goldschmidt, H., Sonneveld, P., Johnsen, H.E., Blade, J., San‐Miguel, J.F. & Palumbo, A. ( 2011 ) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 37, 266 – 283.en_US
dc.identifier.citedreferenceDurie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. ( 2006 ) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467 – 1473.en_US
dc.identifier.citedreferenceGreipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet‐Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. ( 2005 ) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412 – 3420.en_US
dc.identifier.citedreferenceHideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. ( 2001 ) The proteasome inhibitor PS‐341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071 – 3076.en_US
dc.identifier.citedreferenceHuang, H.Q., Brady, M.F., Cella, D. & Fleming, G. ( 2007 ) Validation and reduction of FACT/GOG‐Ntx subscale for platinum/paclitaxel‐induced neurologic symptoms: a gynecologic oncology group study. International Journal of Gynecological Cancer, 17, 387 – 393.en_US
dc.identifier.citedreferenceKanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N. & Ichihara, A. ( 1991 ) Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Research, 51, 6677 – 6685.en_US
dc.identifier.citedreferenceKane, R.C., Bross, P.F., Farrell, A.T. & Pazdur, R. ( 2003 ) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist, 8, 508 – 513.en_US
dc.identifier.citedreferenceKirk, C.J., Jiang, J., Muchamuel, T., Dajee, M., Swinarski, D., Aujay, M., Bennett, M.K., Yang, J., Lewis, E., Laidig, G. & Molineaux, C.J. ( 2008 ) The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration. Blood (ASH Annual Meeting Abstracts), 112, A2765.en_US
dc.identifier.citedreferenceKuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan‐Khan, A.A. & Orlowski, R.Z. ( 2007 ) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin‐proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281 – 3290.en_US
dc.identifier.citedreferenceKyle, R.A. & Rajkumar, S.V. ( 2008 ) Multiple myeloma. Blood, 111, 2962 – 2972.en_US
dc.identifier.citedreferenceLaubach, J.P., Richardson, P.G. & Anderson, K.C. ( 2010 ) The evolution and impact of therapy in multiple myeloma. Medical Oncology, 27 ( Suppl 1 ), S1 – S6.en_US
dc.identifier.citedreferenceMartin, T., Singhal, S.B., Vij, R.M.W., Stewart, A.K., Jagganath, S., Lonial, S., Jakubowiak, A.J., Kukreti, V., Bahlis, N.J., Alsina, M., Chanan‐Khan, A.A., Somlo, G., Buadi, F., Reu, F.J., Zonder, J.A., Song, K., Stadtmauer, E.A., Wong, A.F., Vallone, M., Chang, Y.‐L., Kauffman, M., Orlowski, R.Z. & Siegel, D.S.D. ( 2010 ) Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a phase 2 trial In patients with relapsed and refractory multiple myeloma (R/R MM). Blood (ASH Annual Meeting Abstracts), 116, A3031.en_US
dc.identifier.citedreferenceMohty, B., El‐Cheikh, J., Yakoub‐Agha, I., Moreau, P., Harousseau, J.L. & Mohty, M. ( 2010 ) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 95, 311 – 319.en_US
dc.identifier.citedreferenceMohty, B., El‐Cheikh, J., Yakoub‐Agha, I., Avet‐Loiseau, H., Moreau, P. & Mohty, M. ( 2012 ) Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia, 26, 73 – 85.en_US
dc.identifier.citedreferenceMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., Arnulf, B., Kropff, M., Cavet, J., Esseltine, D.L., Feng, H., Girgis, S., van de Velde, H., Deraedt, W. & Harousseau, J.L. ( 2011 ) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non‐inferiority study. The Lancet Oncology, 12, 431 – 440.en_US
dc.identifier.citedreferenceNiesvizky, R., Richardson, P.G., Rajkumar, S.V., Coleman, M., Rosinol, L., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Boral, A.L., Esseltine, D.L., Anderson, K.C. & Blade, J. ( 2008 ) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 143, 46 – 53.en_US
dc.identifier.citedreferencePapadopoulos, K., Lee, P., Singhal, S., Holahan, J., Tolcher, A., Patnaik, A., Vesole, D., Rosen, S., Rosen, P., Bilotti, E., Woo, T., Lee, S., Hannah, A. & Siegel, D. ( 2011 ) PX‐171‐007: a phase 1b study evaluating the safety and efficacy of a 30‐minute IV infusion of carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma (MM) (Abstract 0898). Haematologica (Abstracts from the 16th Annual Congress of the EHA), 96, 374.en_US
dc.identifier.citedreferenceParlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., Micklem, D.R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K.D. & Bennett, M.K. ( 2009 ) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin‐like activity of the proteasome. Blood, 114, 3439 – 3447.en_US
dc.identifier.citedreferencePlosker, G.L. ( 2008 ) Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs, 68, 2535 – 2551.en_US
dc.identifier.citedreferenceRajkumar, S.V. ( 2009 ) Multiple myeloma. Current Problems in Cancer, 33, 7 – 64.en_US
dc.identifier.citedreferenceRichardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San‐Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. ( 2005 ) Bortezomib or high‐dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 – 2498.en_US
dc.identifier.citedreferenceSiegel, D., Martin, T., Wang, M., Vij, R., Jakubowiak, A.J., Jagannath, S., Lonial, S., Kukreti, V., Bahlis, N.J., Alsina, M., Chanan‐Khan, A.A., Somlo, G., Buadi, F., Reu, F.J., Zonder, J.A., Song, K., Stadtmauer, E., Wong, A.F., Vallone, M., Chang, Y.‐L., Kauffman, M., Orlowski, R.Z., Stewart, A.K. & Singhal, S.B. ( 2010 ) The multiple myeloma research consortium results of PX‐171‐003‐A1, an open‐label, single‐arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 116, A985.en_US
dc.identifier.citedreferenceSiegel, R., Ward, E., Brawley, O. & Jemal, A. ( 2011a ) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians, 61, 212 – 236.en_US
dc.identifier.citedreferenceSiegel, S., Kaufman, J., Wang, M., Martin, T., Jagannath, S., Niesvizky, R., Reu, F., Alsina, M., Badros, A., Gabrail, N., Kukreti, V., Singhal, S., Le, M., Kotlovker, D., Bomba, D., Hannah, A. & Vij, R. ( 2011b ) A summary of safety and efficacy data achieved with long‐term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R MM) Haematologica, 96, 126, Abstract 0302.en_US
dc.identifier.citedreferenceSiegel, D., Martin, T., Wang, M., Vij, R., Lonial, S., Kukreti, V., Bahlis, N., Alsina, M., Somlo, G., Buadi, F., Reu, F., Song, K., Kunkel, L.A., Wong, A.F., Vallone, M., Orlowski, R., Stewart, A.K., Singhal, S., Jagannath, S. & Jakubowiak, A. ( 2011c ) PX‐171‐003‐A1, an open‐label, single‐arm phase (Ph) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long‐term follow‐up and subgroup analysis. Journal of Clinical Oncology (Meeting Abstracts), 29, Abstract 8027.en_US
dc.identifier.citedreferenceSinghal, S., Siegel, D.S., Martin, T., Vij, R., Wang, L., Jakubowiak, A.J., Lonial, S., Kukreti, V., Zonder, J.A., Wong, A.F., McCulloch, L., Badros, A.Z., Niesvizky, R., Orlowski, R.Z., Stewart, A.K., Kotlovker, D. & Jagannath, S. ( 2011 ) Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood (ASH Annual Meeting Abstracts), 118, Abstract 1876.en_US
dc.identifier.citedreferenceVij, R., Kaufman, J.L., Jakubowiak, A.J., Stewart, A.K., Jagannath, S., Kukreti, V., McDonagh, K.T., Alsina, M., Bahlis, N.J., Belch, A., Reu, F.J., Gabrail, N.Y., Matous, J., Vesole, D.H., Orlowski, R.Z., Le, M.H., Lee, P., Wang, M. & the Multiple Myeloma Research Consortium. ( 2010 ) Carfilzomib: high single agent response rate with minimal neuropathy even in high‐risk patients (Abstract). Blood (ASH Annual Meeting Abstracts), 116; Abstract 1938.en_US
dc.identifier.citedreferenceVij, R., Wang, M., Kaufman, J., Lonial, S., Jakubowiak, A., Stewart, A., Kukreti, V., Jagannath, S., McDonagh, K., Alsina, M., Bahlis, N., Reu, F., Gabrail, N., Belch, A., Matous, J., Lee, P., Rosen, P., Sebag, M., Vesole, D., Kunkel, L., Wear, S., Wong, A., Orlowski, R. & Siegel, D.S. ( 2012 ) An open‐label, single‐arm, phase 2 (PX‐171‐004) study of single‐agent carfilzomib in bortezomib‐naïve patients with relapsed and/or refractory multiple myeloma. Blood, 119, 5661 – 5670.en_US
dc.identifier.citedreferenceACS. ( 2012 ). Cancer Facts & Figures 2012. American Cancer Society Inc., Atlanta, GA, USA.en_US
dc.identifier.citedreferenceAlsina, M., Trudel, S., Vallone, M., Molineaux, C., Kunkel, L. & Goy, A. ( 2007 ) Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR‐171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts), 110, A411.en_US
dc.identifier.citedreferenceArastu‐Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J. & Kirk, C.J. ( 2011 ) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical Cancer Research, 17, 2734 – 2743.en_US
dc.identifier.citedreferenceBlade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. ( 1998 ) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high‐dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology, 102, 1115 – 1123.en_US
dc.identifier.citedreferenceBoyette‐Davis, J.A., Cata, J.P., Zhang, H., Driver, L.C., Wendelschafer‐Crabb, G., Kennedy, W.R. & Dougherty, P.M. ( 2011 ) Follow‐up psychophysical studies in bortezomib‐related chemoneuropathy patients. Journal of Pain, 12, 1017 – 1024.en_US
dc.identifier.citedreferenceBringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., Callea, V., Rizzo, V., Cangialosi, C., Musto, P., De Rosa, L., Liberati, A.M., Grasso, M., Falcone, A.P., Evangelista, A., Cavo, M., Gaidano, G., Boccadoro, M. & Palumbo, A. ( 2010 ) Efficacy and safety of once‐weekly bortezomib in multiple myeloma patients. Blood, 116, 4745 – 4753.en_US
dc.identifier.citedreferenceDemo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. & Bennett, M.K. ( 2007 ) Antitumor activity of PR‐171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383 – 6391.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh9232.pdf
Size:
198.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.